Lv1
30 积分 2022-10-12 加入
KN046, a bispecific antibody against PD-L1 and CTLA-4, plus chemotherapy as first-line treatment for metastatic NSCLC: A multicenter phase 2 trial
2小时前
已完结
Brief report: Ivonescimab combined with etoposide plus carboplatin as first-line treatment for extensive-stage small-cell lung cancer: results of a phase Ib clinical trial
1个月前
已完结
Targeting the EGFR signalling pathway in metastatic colorectal cancer
2个月前
已完结
Response and Resistance to RAS Inhibition in Cancer
2个月前
已完结
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study
3个月前
已完结
AdvanTIG-202: Phase 2 open-label, two-cohort multicenter study of ociperlimab plus tislelizumab and tislelizumab alone in patients with previously treated recurrent or metastatic cervical cancer
5个月前
已完结
皖公网安备34019202002308
